COVID-19-Related Discussions Dominate Trinity’s TGaS Spring Summit

White Paper on Planning a Drug Launch Amid COVID-19 Released to Summit Attendees, Now Available

WALTHAM, Mass.--()--Trinity Life Sciences, a leader in global life sciences solutions, found that the majority of in-depth discussions at last week’s virtual TGaS Spring Summit focused on how pharmaceutical companies’ commercial operations need to adjust in response to the current pandemic. COVID-19-related topics that were addressed by the 337 pharmaceutical executives included:

  • Implications of delayed clinical trials
  • Next steps for field force re-entry (state and local guidelines, obtaining appropriate quantities of personal protective equipment (PPE), planning virtual POA/launch meetings, managing 2020 sales awards and performance appraisals)
  • Effective decision making and scenario planning (timing, key considerations and training/certification of customer-facing roles)
  • Long-term impact on business models and workforce behaviors
  • Accelerating the movement to digital strategies and other means of non-personal promotion to interact with healthcare providers in the future
  • Supporting telehealth initiatives and measuring in-market physician engagement

“As our biggest, and arguably, most important Summit to date, we were pleased to serve as a facilitator of conversation and provide insights and analytics on the major topics directly impacting pharma today,” said Gary McWalters, President of TGaS Advisors, a Division of Trinity. “It was no surprise that COVID-19-related topics dominated the conversation.”

Drug Launches in the Age of COVID-19

Drug launches during COVID-19 was a significant topic during the Summit. A recent TGaS benchmarking survey showed that 89 percent of companies have had an impact to their pre-launch activities due to COVID-19, with almost half of these companies reporting high impact.

One white paper that was distributed to attendees at the Summit was entitled: Approaching Launch in the Age of COVID-19, The New Normal for Drug Launches: How to Shift and Stay Ahead of the Curve. The paper finds that there are four “must-have” needs to set the stage for a successful launch during the pandemic:

  1. Recognize and adopt a mindset of change
  2. Customer-driven flexibility
  3. Organizational flexibility: planning, communication and alignment
  4. Data-driven flexibility

“The show must go on,” said Curt Staab, SVP, TGaS Advisors, a division of Trinity. “Drugs will and must launch during this pandemic, but a shift in mindset is needed to ensure success. The needs we detail in this paper are not new, they have been taking root for many years, but COVID-19 is bringing them to the surface and accelerating the need for pharma teams to be flexible and agile.”

A copy of Approaching Launch in the Age of COVID-19, The New Normal for Drug Launches: How to Shift and Stay Ahead of the Curve can be acquired on TrinityLifeSciences.com.

About Trinity Life Sciences

Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.

Contacts

Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

Contacts

Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com